Business Context and Reporting Period
This Form 6-K filing by NLS Pharmaceutics Ltd. (also referenced as Newcelx Ltd. in metadata) covers the period ending October 10, 2024. The company is a foreign private issuer headquartered in Zurich, Switzerland, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The primary material change reported is the company's regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. As of October 10, 2024, the company's common shares traded above $1.00 for ten consecutive trading days.
Guidance, Outlook, and Risks
Management commentary is limited to the confirmation of Nasdaq compliance. The filing does not contain forward-looking guidance, updated risk factors, contingencies, or unusual items. The report is incorporated by reference into the company's Registration Statements on Form F-3.
Investor Verification Checklist
- Verify the current trading price of NLS Pharmaceutics Ltd. shares to ensure continued compliance with the $1.00 minimum bid price.
- Confirm the company's status on Nasdaq to ensure no further delisting notices have been issued.
- Review the referenced Form F-3 Registration Statements (File Nos. 333-262489, 333-268690, and 333-269220) for updated financial data not included in this 6-K.